COLORADO SPRINGS: A drug is under development that could be used as an adjunct to anti-psychotics improved cognitive impairment in patients with schizophrenia, according to data from a randomized, controlled Phase II trial.
Encenicline, which is being developed by Forum Pharmaceuticals, is intended to address cognitive impairment, something that impacts almost all people with schizophrenia, but which is not adequately addressed by anti-psychotics. The drug is an α-7 nicotinic acetylcholine receptor partial agonist…